Literature DB >> 14645695

Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.

H P Kourea1, A K Koutras, C D Scopa, M N Marangos, E Tzoracoeleftherakis, D Koukouras, H P Kalofonos.   

Abstract

AIMS: To look for correlations between expression of cell cycle regulatory proteins p34(cdc2), p21(WAF1), and p53 in node negative invasive ductal breast carcinoma, or between these proteins and clinicopathological parameters, and to assess their prognostic value.
METHODS: Immunohistochemistry using formalin fixed, paraffin wax embedded sections from 94 breast carcinomas. Adjacent benign epithelial breast tissue was available in 74 cases. Median follow up was 72 months.
RESULTS: Nuclear and cytoplasmic p34(cdc2) expression was seen in 80 and 62 tumours, respectively; nuclear expression was seen in adjacent benign epithelium in 12 cases. p21(WAF1) and p53 were positive in 48 and 21 tumours, respectively. High expression of p34(cdc2) in neoplastic nuclei was associated with higher histological grade and p53 expression, but not with tumour size, steroid receptor status, patient age, menopausal status, recurrence, metastasis, disease free survival (DFS), or overall survival (OS). p34(cdc2) in tumour cytoplasm was associated with p34(cdc2) nuclear positivity, high tumour grade, and DFS in univariate but not multivariate analysis. In contrast, p34(cdc2) expression in benign tissue independently predicted DFS and OS in univariate and multivariate analysis. Expression of p53 was associated with high tumour grade and negative steroid receptors, but not with recurrence, metastasis, DFS, or OS. p21(WAF1) expression was not associated with the examined parameters.
CONCLUSIONS: p34(cdc2), p21(WAF1), and p53 expression does not predict outcome in node negative breast carcinoma, although p34(cdc2) expression in benign tissue is related to prognosis. The association between p34(cdc2) and p53 implicates p53 in G2-M cell cycle checkpoint control, possibly via mediators unrelated to p21(WAF1).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645695      PMCID: PMC1187351          DOI: 10.1136/mp.56.6.328

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  56 in total

1.  Expression of the G2-M checkpoint regulators cyclin B1 and P34CDC2 in breast cancer: a correlation with cellular kinetics.

Authors:  T Megha; S Lazzi; F Ferrari; R Vatti; C M Howard; G Cevenini; L Leoncini; P Luzi; A Giordano; P Tosi
Journal:  Anticancer Res       Date:  1999 Jan-Feb       Impact factor: 2.480

2.  A measure of the mitotic index: studies of the abundance and half-life of p34cdc2 in cultured cells and normal and neoplastic tissues.

Authors:  J V Gannon; A Nebreda; N M Goodger; P R Morgan; T Hunt
Journal:  Genes Cells       Date:  1998-01       Impact factor: 1.891

3.  p53 regulates a G2 checkpoint through cyclin B1.

Authors:  S A Innocente; J L Abrahamson; J P Cogswell; J M Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 4.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

Review 5.  Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

Authors:  P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

6.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.

Authors:  P P Rosen; M L Lesser; C D Arroyo; M Cranor; P Borgen; L Norton
Journal:  J Clin Oncol       Date:  1995-04       Impact factor: 44.544

7.  p34cdc2 in invasive breast cancer: relationship to DNA content, Ki67 index and c-erbB-2 expression.

Authors:  B Wiesener; C E Hauser-Kronberger; E Zipperer; O Dietze; C Menzel; G W Hacker
Journal:  Histopathology       Date:  1998-12       Impact factor: 5.087

8.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.

Authors:  A D Thor; I I Moore DH; S M Edgerton; E S Kawasaki; E Reihsaus; H T Lynch; J N Marcus; L Schwartz; L C Chen; B H Mayall
Journal:  J Natl Cancer Inst       Date:  1992-06-03       Impact factor: 13.506

9.  Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival.

Authors:  S E Pinder; P Wencyk; D M Sibbering; J A Bell; C W Elston; R Nicholson; J F Robertson; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

10.  A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.

Authors:  R Michalides; P Hageman; H van Tinteren; L Houben; E Wientjens; R Klompmaker; J Peterse
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more
  9 in total

1.  Over-expression of p53, p21 and Cdc2 in histologically negative surgical margins is correlated with local recurrence of laryngeal squamous cell carcinoma.

Authors:  Jun-Quan Yang; Hong-Xia Liu; Zhen Liang; Yu-Man Sun; Meng Wu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Overexpressions of Cyclin B1, cdc2, p16 and p53 in human breast cancer: the clinicopathologic correlations and prognostic implications.

Authors:  Seoung Wan Chae; Jin Hee Sohn; Dong-Hoon Kim; Yoon Jung Choi; Yong Lai Park; Kyungeun Kim; Young Hye Cho; Jung-Soo Pyo; Jun Ho Kim
Journal:  Yonsei Med J       Date:  2011-05       Impact factor: 2.759

3.  Effect of indomethacin on cell cycle proteins in colon cancer cell lines.

Authors:  Mei-Hua Xu; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

Review 4.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

5.  Feature genes in metastatic breast cancer identified by MetaDE and SVM classifier methods.

Authors:  Youlin Tuo; Ning An; Ming Zhang
Journal:  Mol Med Rep       Date:  2018-01-09       Impact factor: 2.952

6.  Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors.

Authors:  Shazia Sofi; Umar Mehraj; Hina Qayoom; Shariqa Aisha; Abdullah Almilaibary; Mustfa Alkhanani; Manzoor Ahmad Mir
Journal:  Med Oncol       Date:  2022-06-20       Impact factor: 3.738

7.  FOXC2 regulates the G2/M transition of stem cell-rich breast cancer cells and sensitizes them to PLK1 inhibition.

Authors:  Mika Pietilä; Geraldine V Vijay; Rama Soundararajan; Xian Yu; William F Symmans; Nathalie Sphyris; Sendurai A Mani
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

8.  Both p62/SQSTM1-HDAC6-dependent autophagy and the aggresome pathway mediate CDK1 degradation in human breast cancer.

Authors:  María Galindo-Moreno; Servando Giráldez; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  Sci Rep       Date:  2017-08-30       Impact factor: 4.379

9.  Integrated bioinformatics analysis reveals key candidate genes and pathways in breast cancer.

Authors:  Yuzhi Wang; Yi Zhang; Qian Huang; Chengwen Li
Journal:  Mol Med Rep       Date:  2018-04-19       Impact factor: 2.952

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.